Clopidogrel for the hot patient

Circulation: Cardiovascular Interventions

Volumn 2, Issue 6, 2009, Pages 495-496

  Bilodeau, Matthew L ^a   Simon, Daniel I ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Clopidogrel; Editorials; Inflammation; Platelets; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CELL ADHESION MOLECULE; CLOPIDOGREL; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PRASUGREL; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROSTACYCLIN; THROMBOMODULIN; TICAGRELOR;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CELL ADHESION; CELLULAR STRESS RESPONSE; CORONARY ARTERY DISEASE; EDITORIAL; ENDOTHELIUM CELL; HEART DEATH; HEART INFARCTION; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; MONOCYTE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; STROKE; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RISK ASSESSMENT; STROKE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 77953676530     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.109.921577     Document Type: Editorial

References (21)

1. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
2. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: Linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54:669-677.
3. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA. 1997;94:1931-1936.
4. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller- Berghaus G, Kroczek RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591-594.
5. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394:200 -203.
6. Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res. 1997;81:448-454.
7. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, Phillips DR, Wagner DD. CD40L stabilizes arterial thrombi by a beta3 integrin- dependent mechanism. Nat Med. 2002;8:247-252.
8. Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med. 2003;9:61- 67.
9. Massberg S, Brand K, Gruner S, Page S, Muller E, Muller I, Bergmeier W, Richter T, Lorenz M, Konrad I, Nieswandt B, Gawaz M. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887- 896.
10. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718 -1720.
11. Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-167.
12. Versaci F, Gaspardone A, Tomai F, Ribichini F, Russo P, Proietti I, Ghini AS, Ferrero V, Chiariello L, Gioffre PA, Romeo F, Crea F. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40:1935-1942.
13. Gurbel PA, Bliden KP, Tantry US. Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol. 2006;48:2186 -2191.
14. Welt FG, Rogers SD, Zhang X, Ehlers R, Chen Z, Nannizzi-Alaimo L, Phillips DR, Simon DI. GP IIb/IIIa inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention. Catheter Cardiovasc Intervent. 2004;61:185-189
15. Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Boger R, Baldus S. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006;26:1648 -1652.
16. Yip HK, Chang LT, Sun CK, Yang CH, Hung WC, Cheng CI, Chua S, Yeh KH, Wu CJ, Fu M. Impact of clopidogrel on suppression of circulating levels of soluble CD40 ligand in patients with unstable angina undergoing coronary stenting. Am J Cardiol. 2006;97:192-194.
17. Dosh K, Berger PB, Marso SP, van Lente F, Brennan DM, Charnigo R, Topol EJ, Steinhubl SR. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events following percutaneous coronary intervention: an analysis from the Clopidogrel for the Reduction of Events During Observation Trial. Circ Cardiovasc Interv. 2009;2:503-512.
18. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc. 2002;288:2411-2420.
19. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc. 2001;286:2107-2113.
20. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
21. Peters RJ, Mehta SR, Fox KA, Zhao F, Lewis BS, Kopecky SL, Diaz R,Commerford PJ, Valentin V, Yusuf S. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108:1682-1687.